Gene:
DRD2
dopamine receptor D2

PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx, click here.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Position ? Drug ? Relevance ? Strength of
Evidence ?
rs6277

To see relevance please register or sign in.

2
rs1079598

To see relevance please register or sign in.

2
rs1799978

To see relevance please register or sign in.

2
rs1799978

To see relevance please register or sign in.

2
rs1799978

To see relevance please register or sign in.

2
rs1799732

To see relevance please register or sign in.

3

Download a summary of all Clinical Annotations available.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

PharmGKB contains no genetic tests for this gene. To report genetic tests, click here.

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(build 132)
Alternate Names ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs1076560
C > A
Intronic
No VIP available CA VA
rs1079598 c.-31-870T>C, g.16858690A>G, g.54728T>C
A > G
Intronic
No VIP available No Clinical Annotations available VA
rs1110976
T > G
Intronic
No VIP available No Clinical Annotations available VA
rs1125394
T > C
Intronic
rs1799732 DRD2: -141C Ins/Del, g.16908668_16908669insG, g.4749_4750insC
- > G
5' Flanking
No VIP available CA VA
rs1799978 DRD2: -241A>G, DRD2:A-241G, g.16908767T>C, g.4651A>G
T > C
5' Flanking
VIP No Clinical Annotations available No Variant Annotations available
rs1800497 32806C>T, DRD2 Taq1A, DRD2:32806C>T, DRD2:Taq1A, DRD2:Taq1A A1, DRD2:TaqIA allele, Taq1A, c.2137G>A, g.112776038G>A, g.16833244G>A, g.16833244G>C, g.16833244G>T, g.17316G>A, p.Glu713Lys
G > A
Missense
Glu713Lys
rs1801028 DRD2:1097C>G, DRD2:Ser311Cys, c.845C>G, c.932C>G, g.16845900G>C, g.67518C>G, p.Ser282Cys, p.Ser311Cys
G > C
Missense
Ser311Cys
No VIP available No Clinical Annotations available VA
rs2283265
C > A
Intronic
No VIP available No Clinical Annotations available VA
rs4436578
C > T
Intronic
No VIP available No Clinical Annotations available VA
rs4648317
G > A
Intronic
No VIP available No Clinical Annotations available VA
rs6275
A > G
Synonymous
His284His
No VIP available No Clinical Annotations available VA
rs6276 DRD2: A1385G, c.*52G>A, g.16843813C>T, g.69605G>A
C > T
3' UTR
rs6277 C957T, DRD2: C957T, DRD2:1035C>T, DRD2:1122C>T, DRD2:957C>T, c.870C>T, c.957C>T, g.16845875G>A, g.67543C>T
G > A
Synonymous
Pro319Pro
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132

Overview

Alternate Names:  D(2) dopamine receptor; dopamine D2 receptor; dopamine receptor D2 isoform; seven transmembrane helix receptor
Alternate Symbols:  D2DR; D2R
PharmGKB Accession Id: PA27478

Details

Cytogenetic Location: chr11 : q23.2 - q23.2
GP mRNA Boundary: chr11 : 113280317 - 113346001
GP Gene Boundary: chr11 : 113277317 - 113356001
Strand: minus
Product Name: No data available
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics
    Representation of genes involved in nicotine effects in dopaminergic neurons.

External Pathways

Links to non-PharmGKB pathways.

  1. regulation of ck1/cdk5 by type 1 glutamate receptors - (BioCarta via Pathway Interaction Database)
No related genes are available

Curated Information ?

Evidence Drug Class
antipsychotics

Curated Information ?

Publications related to DRD2: 84

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. [Article:21289622@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The aldehyde dehydrogenase 2 gene is associated with heroin dependence. Drug and alcohol dependence. 2011. Wang Tzu-Yun, et al. [Article:21723677@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine-related genes and spontaneous smoking cessation in ever-heavy smokers. Pharmacogenomics. 2011. Breitling Lutz P, et al. [Article:21806388@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics. 2011. Hwang Rudi, et al. [Article:21332319@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011. Hung Chin-Chuan, et al. [Article:21902500@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics. 2011. Risselada Arne J, et al. [Article:21843067@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics. 2011. Zhang Xiang Rong, et al. [Article:21749219@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. The American journal of psychiatry. 2011. Greenwood Tiffany A, et al. [Article:21498463@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: a preliminary study. BMC medical genetics. 2010. Prasad Pushplata, et al. [Article:20146828@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
An association analysis of circadian genes in anxiety disorders. Biological psychiatry. 2010. Sipilä Tessa, et al. [Article:20122683@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. [Article:20981002@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas. Expert opinion on drug metabolism & toxicology. 2010. Filopanti M, et al. [Article:19929252@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010. Lohoff Falk W, et al. [Article:20102306@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Intronic Polymorphisms Affecting Alternative Splicing of Human Dopamine D2 Receptor Are Associated with Cocaine Abuse. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Moyer Robert A, et al. [Article:21150907@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and genomics. 2010. Lencz Todd, et al. [Article:20664489@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenetics and genomics. 2010. Hong Chen-Jee, et al. [Article:20375926@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: dopamine receptor D2. Pharmacogenetics and genomics. 2010. Mi Huaiyu, et al. [Article:20736885@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:20648701@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette Syndrome. Pharmacogenomics. 2010. Liao Isaac H, et al. [Article:21142917@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics. 2010. De Ruyck Kim, et al. [Article:20712524@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010. McCarthy Michael J, et al. [Article:21047205@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. [Article:20860469@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective association of dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics. 2010. Breitling Lutz P, et al. [Article:20350135@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Progress in neuro-psychopharmacology & biological psychiatry. 2010. Dubertret Caroline, et al. [Article:20138949@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. The American journal of psychiatry. 2010. Zhang Jian-Ping, et al. [Article:20194480@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. The pharmacogenomics journal. 2010. Liu W, et al. [Article:21173788@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The pharmacogenomics journal. 2010. Müller D J, et al. [Article:20714340@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetics of dopamine receptors and drug addiction: a comprehensive review. Behavioural pharmacology. 2009. Le Foll Bernard, et al. [Article:19179847@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clozapine, GABA(B), and the treatment of resistant schizophrenia. Clinical pharmacology and therapeutics. 2009. Daskalakis Z J, et al. [Article:19626000@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predicting age-specific dosing of antipsychotics. Clinical pharmacology and therapeutics. 2009. Uchida H, et al. [Article:19763115@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. European journal of clinical pharmacology. 2009. Liu Ying-Zi, et al. [Article:19396436@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Journal of psychiatric research. 2009. Shen Yu-Chih, et al. [Article:18926547@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2009. Munafò Marcus R, et al. [Article:19246443@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. Pharmacogenetics and genomics. 2009. Kraschewski Adrian, et al. [Article:19603545@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenetics and genomics. 2009. Doehring Alexandra, et al. [Article:19373123@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics. 2009. Calarge Chadi A, et al. [Article:19339912@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics. 2009. Gupta Meenal, et al. [Article:19207030@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic modulation of the pharmacological treatment of pain. Pharmacology & therapeutics. 2009. Lötsch Jörn, et al. [Article:19615406@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Movement disorders associated with aripiprazole use: a case series. The International journal of neuroscience. 2009. Hall Deborah A, et al. [Article:19916856@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. The pharmacogenomics journal. 2009. Gassó P, et al. [Article:19506579@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of psychiatric research. 2008. Alenius Malin, et al. [Article:18086475@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular psychiatry. 2008. Bakker P R, et al. [Article:18180754@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature genetics. 2008. Allen Nicole C, et al. [Article:18583979@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2008. Childs Emma, et al. [Article:18305461@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and genomics. 2008. Kohlrausch Fabiana B, et al. [Article:18551040@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. Pharmacogenetics and genomics. 2008. Kim Euitae, et al. [Article:18192895@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics. 2008. Thelma Bk, et al. [Article:18781856@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. 2008. Ikeda Masashi, et al. [Article:18855532@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Progress in neuro-psychopharmacology & biological psychiatry. 2008. Crettol Séverine, et al. [Article:18687376@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science (New York, N.Y.). 2008. Stice E, et al. [Article:18927395@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. The pharmacogenomics journal. 2008. Filopanti M, et al. [Article:18332900@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Molecular psychiatry. 2007. Zai C C, et al. [Article:17767146@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association analysis of the dopamine receptor D2 (DRD2) SNP rs1076560 in alcoholic patients. Neuroscience letters. 2007. Sasabe Toshikazu, et al. [Article:17196743@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenetics and genomics. 2007. Aklillu Eleni, et al. [Article:18075468@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007. Xing Qinghe, et al. [Article:17105675@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. The pharmacogenomics journal. 2007. Robinson J D, et al. [Article:17189962@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. Journal of clinical psychopharmacology. 2006. Hedenmalm Karin, et al. [Article:16633151@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. Lerman Caryn, et al. [Article:16123753@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. The American journal of psychiatry. 2006. Lencz Todd, et al. [Article:16513877@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatric disease and treatment. 2005. Lotrich Francis E, et al. [Article:18568127@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neuroscience letters. 2005. Wu Shengnan, et al. [Article:15694263@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Progress in neuro-psychopharmacology & biological psychiatry. 2005. Corripio Iluminada, et al. [Article:15610950@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 2005. Hwang Rudi, et al. [Article:15830237@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2003. Noble Ernest P. [Article:12497624@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human molecular genetics. 2003. Duan Jubao, et al. [Article:12554675@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. The pharmacogenomics journal. 2003. Yamanouchi Y, et al. [Article:14610521@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics. 2001. Suzuki A, et al. [Article:11505224@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics. 2000. Makoff A J, et al. [Article:10739171@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A global survey of haplotype frequencies and linkage disequilibrium at the DRD2 locus. Human genetics. 1998. Kidd K K, et al. [Article:9760208@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 1998. Arranz M J, et al. [Article:9918131@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry research. 1998. Ohara K, et al. [Article:9858029@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Dopamine D2 receptors in signal transduction and behavior. Critical reviews in neurobiology. 1997. Picetti R, et al. [Article:9209827@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human molecular genetics. 1997. Arinami T, et al. [Article:9097961@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Evolution of haplotypes at the DRD2 locus. American journal of human genetics. 1995. Castiglione C M, et al. [Article:8533775@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Linkage disequilibria at the D2 dopamine receptor locus (DRD2) in alcoholics and controls. Genomics. 1994. Suarez B K, et al. [Article:7910578@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA : the journal of the American Medical Association. 1994. Gejman P V, et al. [Article:8277546@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Schizophrenia: normal sequence in the dopamine D2 receptor region that couples to G-proteins. DNA polymorphisms in D2. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1993. Seeman P, et al. [Article:8471125@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics. 1991. Hauge X Y, et al. [Article:1679742@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor. Genomics. 1991. Sarkar G, et al. [Article:1837284@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A new TaqI RFLP within intron 2 of human dopamine D2 receptor gene (DRD2). Nucleic acids research. 1991. Parsian A, et al. [Article:1684859@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism. JAMA : the journal of the American Medical Association. 1990. Bolos A M, et al. [Article:1979357@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. American journal of human genetics. 1989. Grandy D K, et al. [Article:2573278@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 1989. Giros B, et al. [Article:2531847@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cloning of the cDNA and gene for a human D2 dopamine receptor. Proceedings of the National Academy of Sciences of the United States of America. 1989. Grandy D K, et al. [Article:2532362@PubMed]
PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.